Building the future of eye diagnostics
Early Detection
Supports the identification of suspected uveal melanoma from retinal images.
Clinical Validation
Currently being evaluated in pilot collaborations and progressing toward CE-MDR submission.
Ophthalmology Platform
Combining clinical expertise, retinal imaging and machine learning in a platform designed for future ophthalmology applications.
For Opticians and Ophthalmologists
Eyedentity supports opticians and ophthalmologists by providing a risk assessment based on retinal images, helping reduce unnecessary referrals while maintaining high sensitivity for malignant cases.
Built on clinical evidence
The model is developed using unique, longitudinal clinical data and validated in peer-reviewed studies. Eyedentity is designed to integrate into existing imaging workflows and support clinical judgment.
Early detection changes outcomes
We equip eye care professionals with AI-powered decision support that uncovers risk sooner, improves confidence, and fits naturally into daily clinical practice.
News and Updates
August 2026: Capital round closed
Eyedentity is now supported by leading life science and impact investors, with Karolinska Institutet Innovations and Norrsken Launcher helping us develop Eyedentity platform toward clinical use.
May 2026: melAInoma pilot program started
Our first real world pilot of melAInoma is now running in selected optometry practices, providing early experience and data from routine patient care. The pilot will help us fine tune the workflow and prepare for broader clinical use in detecting uveal melanoma earlier.
April 2026: melAInoma featured in National TV
A recent feature by Sveriges Television highlights how AI can support earlier detection of aggressive eye cancer. The work, led by Gustav Stålhammar at Karolinska Institutet and St. Erik Eye Hospital, is now moving towards real-world use.
Watch the segment
February 2026: Comparison of MOLES and melAInoma
In a recent open-access paper in Cancers (MDPI), Gustav Stålhammar presents work on how Eyedentity’s AI system, melAInoma, can analyse routine fundus photographs to support the triage of melanocytic choroidal lesions
Read the article
January 2026: Eyedentity at Optikmässan
Eyedentity at Optikmässan.Friday 17 January, 11:45 - 12:45Lecture: AI support for early detection of ocular melanoma — Gustav Stålhammar, MD, PhD
Read more about the session
January 2026: Professor Gustav Stålhammar highlighted
Our CSO, Professor Gustav Stålhammar, is currently ranked #4 globally in uveal melanoma research over the past five years
Scholar GPS
2025: Validation of melAInoma
Recent studies demonstrate that melAInoma significantly improves diagnostic accuracy compared to standard assessment, while reducing false referrals.The results are based on longitudinal clinical data and external validation.
Read the article
2025: AI decision support in optometric practice
AI is becoming an important part of modern eye care.This article discusses how decision support tools can strengthen opticians’ clinical role and improve referral quality.
Read the article
Supported by leading life science and impact investors
Eyedentity is supported by Karolinska Institutet Innovations and Norrsken Launcher as we develop the Eyedentity platform toward clinical use.
Our Team
Eyedentity brings together expertise in ophthalmology, AI, software engineering and medical technology.
- Creator of the melAInoma model and former ML manager RaySearch Laboratories. Brought the world’s first ML-based automated radiation planning product to market
- Background as expert and manager from banking and finance, bridging technology, data and product. CEO and founder of Collaborative Minds, is a senior advisor and entrepreneur focused on AI and data driven products and strategy
- Senior Consultant (överläkare), S:t Eriks Ögonsjukhus. Professor in ophtalmology and research group leader, Karolinska Institutet
- Director of Machine Learning, executive team member, RaySearch Laboratories. PhD in optimization of radiation therapy
- MD, PhD and clicinal expert in ophtalmology at S:t Eriks Ögonsjukhus
